title: Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study.
abstract: OBJECTIVE
  Abdominal obesity, insulin resistance and compensatory hyperinsulinaemia play a central role in the pathogenesis of the polycystic ovary syndrome (PCOS). Abdominal adipose tissue is a source of adipokines, such as adiponectin and resistin, both of which may be involved in the development of insulin resistance and chronic inflammation in PCOS. Ghrelin, an important regulatory peptide of food intake, may also play a role in metabolic disturbances related to PCOS. The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS.
  
  
  METHODS
  A randomised placebo-controlled study.
  
  
  METHODS
  Thirty overweight/obese women with PCOS (body mass index>25 kg/m(2), mean age 29.1+/- 1.2 (S.E.M.) years) were randomly allocated to either rosiglitazone (Avandia, 4 mg twice a day) or placebo treatment. Plasma levels of adiponectin, resistin and ghrelin and their correlation to serum levels of insulin, C-peptide and steroid hormones, and insulin sensitivity (euglycaemic hyperinsulinaemic clamp) were assessed.
  
  
  RESULTS
  Adiponectin and ghrelin levels correlated significantly with most metabolic markers of insulin resistance and with serum levels of DHEA and 17-hydroxyprogesterone. Plasma levels of adiponectin increased from 9.26+/-0.90 (S.E.M.) to 22.22+/-3.66 microg/ml (P<0.001) and those of resistin decreased from 12.57+/-1.63 to 9.21+/-0.53 ng/ml (P=0.009) at 4 months of treatment, but plasma ghrelin levels did not change.
  
  
  CONCLUSIONS
  Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment.
authors.affiliation: Department of Obstetrics and Gynaecology, University Hospital of Oulu, Finland.
authors.forename: A
authors.initials: A
authors.lastname: Majuri
authors.forename: M
authors.initials: M
authors.lastname: Santaniemi
authors.forename: K
authors.initials: K
authors.lastname: Rautio
authors.forename: A
authors.initials: A
authors.lastname: Kunnari
authors.forename: J
authors.initials: J
authors.lastname: Vartiainen
authors.forename: A
authors.initials: A
authors.lastname: Ruokonen
authors.forename: Y A
authors.initials: YA
authors.lastname: Kesäniemi
authors.forename: J S
authors.initials: JS
authors.lastname: Tapanainen
authors.forename: O
authors.initials: O
authors.lastname: Ukkola
authors.forename: L
authors.initials: L
authors.lastname: Morin-Papunen
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D005260:Female; D054439:Ghrelin; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance; D036361:Peptide Hormones / Q000097:blood; D010919:Placebos; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism; D052243:Resistin / Q000097:blood*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D052242:Adiponectin; D054439:Ghrelin; D007004:Hypoglycemic Agents; D036361:Peptide Hormones; D010919:Placebos; D052243:Resistin; D045162:Thiazolidinediones; D000077154:Rosiglitazone